ESR1 and breast carcinoma: To establish model systems for studying mechanisms underlying resistance to endocrine therapies, we chronically exposed ER+ breast cancer cell lines to increasing concentrations of fulvestrant during 9 to 40 weeks until the cells overcame their initial sensitivity to this drug and proliferated well in the presence of 100 nM fulvestrant (Additional file 3A-B).